<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04163783</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-3111-105</org_study_id>
    <nct_id>NCT04163783</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy Males</brief_title>
  <official_title>A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 Following Single Oral Dose Administration in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 study in healthy subjects to determine the effect of an 8-hour fast from food on the
      pharmacokinetics of [14C]-BGB-3111.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be an open-label, non-randomized study to evaluate the pharmacokinetics of
      [14C]-BGB-3111 when administered in healthy male subjects following at least an 8-hour fast
      from food (not including water).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 29, 2017</start_date>
  <completion_date type="Actual">April 18, 2017</completion_date>
  <primary_completion_date type="Actual">April 18, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter: Plasma concentration of [14C]-BGB-3111 as measured by area under concentration-time curve (AUC)</measure>
    <time_frame>Up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter: Maximum Plasma Concentration (Cmax) of [14C]-BGB-3111</measure>
    <time_frame>Up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter: Time To Maximum Plasma Concentration (Tmax) of [14C]-BGB-3111</measure>
    <time_frame>Up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter: apparent terminal elimination rate constant (λZ) of [14C]-BGB-3111</measure>
    <time_frame>Up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter: Half-life Period of (T1/2) of [14C]-BGB-3111</measure>
    <time_frame>Up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter: apparent systemic clearance (CL/F) of [14C]-BGB-3111</measure>
    <time_frame>Up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter: apparent volume of distribution during the terminal phase (Vz/F) of [14C]-BGB-3111</measure>
    <time_frame>Up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood and plasma concentrations of total radioactivity: Maximum Plasma Concentration (Cmax) of [14C]-BGB-3111</measure>
    <time_frame>Up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood and plasma concentrations of total radioactivity: Time To Maximum Plasma Concentration (Tmax) of [14C]-BGB-3111</measure>
    <time_frame>Up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood and plasma concentrations of total radioactivity of [14C]-BGB-3111 as measured by area under concentration-time curve (AUC)</measure>
    <time_frame>Up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood and plasma concentrations of total radioactivity: apparent terminal elimination rate constant (λZ) of [14C]-BGB-3111</measure>
    <time_frame>Up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood and plasma concentrations of total radioactivity: Half-life Period of (T1/2) of [14C]-BGB-3111</measure>
    <time_frame>Up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood and plasma concentrations of total radioactivity: apparent systemic clearance (CL/F) of [14C]-BGB-3111</measure>
    <time_frame>Up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood and plasma concentrations of total radioactivity: apparent volume of distribution during the terminal phase (Vz/F) of [14C]-BGB-3111</measure>
    <time_frame>Up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary recovery of total radioactivity of [14C]-BGB-3111 as assessed by the amount excreted in urine per sampling interval (Aeu)</measure>
    <time_frame>Up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary recovery of total radioactivity of [14C]-BGB-3111 as assessed by the cumulative amount excreted in urine per sampling interval (Cum Aeu)</measure>
    <time_frame>Up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary recovery of total radioactivity of [14C]-BGB-3111 as assessed by the percentage of drug or radioactive dose excreted in urine per sampling interval (%Feu)</measure>
    <time_frame>Up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary recovery of total radioactivity of [14C]-BGB-3111 as assessed by the cumulative percentage of drug or radioactive dose excreted in urine (Cum %Feu)</measure>
    <time_frame>Up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary recovery of total radioactivity as assessed by the renal clearance (CLR; for BGB-3111 only)</measure>
    <time_frame>Up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fecal recovery of total radioactivity as assessed by the amount of [14C]-BGB-3111 excreted in feces per sampling interval (Aef)</measure>
    <time_frame>Up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fecal recovery of total radioactivity as assessed by the cumulative amount of [14C]-BGB-3111 excreted in feces per sampling interval (Cum Aef)</measure>
    <time_frame>Up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fecal recovery of total radioactivity as assessed by the percentage of radioactive dose excreted in feces per sampling interval (%Fef)</measure>
    <time_frame>Up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fecal recovery of total radioactivity as assessed by the cumulative percentage of radioactive dose excreted in feces per sampling interval (Cum %Fef)</measure>
    <time_frame>Up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mass balance</measure>
    <time_frame>Up to 13 days</time_frame>
    <description>Urine and fecal collection for Mass Balance Evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Routes of elimination of [14C]-BGB-3111</measure>
    <time_frame>Up to 13 days</time_frame>
    <description>Urine and fecal collection for Metabolite Profiling/Characterization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize and identify metabolites of [14C]-BGB-3111</measure>
    <time_frame>Up to 13 days</time_frame>
    <description>plasma, urine, and feces collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma and urine concentrations of BGB-3111</measure>
    <time_frame>up to 13 days</time_frame>
    <description>plasma and urine collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants experiencing Adverse events (AEs)</measure>
    <time_frame>up to 13 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants experiencing abnormal clinical laboratory evaluations</measure>
    <time_frame>up to 13 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administered a single oral dose of 320 mg of [14C]-BGB-3111</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-BGB-3111</intervention_name>
    <description>20-mg capsule containing ~200 μCi of [14C]-BGB-3111,</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-3111</intervention_name>
    <description>Three 20-mg capsules of BGB-3111 and three 80-mg capsules of BGB-3111</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male between 18 and 65 years of age, inclusive, at Screening

          2. Body mass index between 18.0 and 35.0 kg/m2, inclusive, at Screening

          3. In good health, determined by no clinically significant findings from medical
             history,12-lead ECGs, or vital signs measurements

          4. Clinical laboratory evaluations

        Exclusion Criteria:

          1. Significant history or clinical manifestation of any metabolic, allergic, infectious,
             dermatological, hepatic, renal, hematological, pulmonary, metabolic, cardiovascular,
             gastrointestinal, neurological, or psychiatric disorder (as determined by the
             Investigator [or designee]) prior to Check-in

          2. History of significant hypersensitivity, intolerance, or allergy to any drug compound,
             food, or other substance, unless approved by the Investigator (or designee) prior to
             Check-in

          3. History of stomach or intestinal surgery or resection that could alter absorption or
             excretion of orally administered drugs prior to Check-in except that appendectomy and
             hernia repair will be allowed if it was not associated with complications

          4. Abnormal liver function tests
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Novotony, MD</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit, Inc.,</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 5, 2019</study_first_submitted>
  <study_first_submitted_qc>November 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2019</study_first_posted>
  <last_update_submitted>November 12, 2019</last_update_submitted>
  <last_update_submitted_qc>November 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zanubrutinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

